The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders

Cancer

Volumn 107, Issue 4, 2006, Pages 773-780

  Polizzotto, Mark N ^a   Tam, Constantine S ^a   Milner, Alvin ^b   Januszewicz, E Henry ^c   Prince, H Miles ^c   Westerman, David ^c   Wolf, Max M ^c   Seymour, John F ^b,c  

^a ALFRED HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Age; Fludarabine chemotherapy; Lymphoid malignancies; Purine analogue; Toxicity

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; RITUXIMAB;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE SEVERITY; FEMALE; HUMAN; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; RISK FACTORS; VIDARABINE;

EID: 33747246256     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22022     Document Type: Article

References (56)

1. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251.
2. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer. 2002;94:2015-2023.
3. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003;97:2229-2235.
4. Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995;75:381-394.
5. Hjalmar V, Carlsson M, Kimby E. Chronic lymphocytic leukaemia at a county hospital in southern Sweden. Med Oncol. 1996;13:95-101.
6. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
7. Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2002;193-213.
8. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
9. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
10. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated Stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
11. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
12. Hochster HS, Kim KM, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1992;10:28-32.
13. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996;14:514-519.
14. Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as front-line treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol. 2000;18:773-779.
15. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7:3580-3589.
16. Crawley CR, Foran JM, Gupta RK, et al. A Phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol. 2000;11:861-865.
17. Ma SY, Au WY, Chim CS, et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol. 2004;124:754-761.
18. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
19. Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol. 2001;12:1455-1460.
20. Tsimberidou AM, Keating MJ, Giles FJ, et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004;100:2583-2591.
21. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol. 2004;22:2654-2661.
22. Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001;42:1015-1022.
23. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
24. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885-891.
25. Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up-a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;18:987-994.
26. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
27. Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer. 2004;100:2181-2189.
28. Santini G, Nati S, Spriano M, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Hematologica. 2001;86:282-286.
29. Schmitt B, Wendtner CM, Bergmann M, et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma. 2002;3:26-35.
30. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-3071.
31. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
32. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
33. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49-53.
34. Tam CS, Wolf MM, Januszewicz EH, et al. A new model for predicting infectious complications during fludarabine-based combinaticn chemotherapy among patients with indolent lymphoid malignancies. Cancer. 2004;101:2042-2049.
35. Tam C, Seymour JF, Brown M, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Hematologica. 2005;90:700-702.
36. Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Hematologica. 2000;85:1268-1270.
37. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
38. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
39. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol. 1989;42:567-584.
40. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419-1432.
41. Thomas DW, Owen RG, Johnson SA, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma. 2005;46:549-552.
42. Blum RH, Seymour JF, Wirth A, MacManus M, Hicks RJ. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2003;4:43-49.
43. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
44. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma International Prognostic Index. Blood. 2004;104:1258-1265.
45. Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to Stage III-IV patients. The GOELAMS Group, France. Ann Oncol. 1997;8(Suppl 1):49-52.
46. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530-2539.
47. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27-34.
48. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-2953.
49. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing hematological toxicity. J Clin Oncol. 1998;16:2352-2358.
50. Yates JW. Comorbidity considerations in geriatric oncology research. CA Cancer J Clin. 2001;51:329-336.
51. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol. 2002;20:494-502.
52. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224-237.
53. Wasil T, Lichtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist 2005;10:602-612.
54. Rudd GN, Hartley JA, Souhami RL. Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals. Cancer Chemother Pharmacol. 1995;35:323-326.
55. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am. 2000;14:193-212, x-xi.
56. Lichtman SM, Etcubanas E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. 2002;20:904-913.